GT 863

Drug Profile

GT 863

Alternative Names: GT863

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Pharmaspur Inc
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 15 Jun 2016 Pharmaspur completes a phase I trial in Alzheimer's disease in Japan (UMIN000021672)
  • 05 Apr 2016 Phase I trials in Alzheimer's disease (In volunteers) in Japan (unspecified route) (UMIN000021672)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top